Kathryn M. Hastie

Kathryn M. Hastie

Auto-generated profile, based on publicly available information

Kathryn M. Hastie

Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Science
Verified
Journal Article
Open access
PDF file
JDJennifer M. Dan
Jennifer M. Dan
JMJose Mateus
Jose Mateus
YKYu Kato
Yu Kato
KHKathryn M. Hastie
Kathryn M. Hastie
YDYu Esther Dawen
Yu Esther Dawen
SCShane Crotty
Shane Crotty
Variable memory: Immune memory against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps to determine protection against reinfection, disease risk, and vaccine efficacy. Using 188 human cases across the range of severity of COVID-19, Dan et al. analyzed cross-sectional data describing the dynamics of SARS-CoV-2 memory B cells, CD8 + T cells, and CD4 + T cells for more than 6 months after infection. The authors found a high degree of heterogeneity in the magnitude of adaptive immune responses that persisted into the immune memory phase to the virus. However, immune memory in three immunological compartments remained measurable in greater than 90% of subjects for more than 5 months after infection. Despite the heterogeneity of immune responses, these results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals. Science , this issue p. eabf4063

23 September 2021 in Science
Verified
Journal Article
Open access
KHKathryn M. Hastie
Kathryn M. Hastie
HLHaoyang Li
Haoyang Li
DBDaniel Bedinger
Daniel Bedinger
SSSharon L. Schendel
Sharon L. Schendel
SDS. Moses Dennison
S. Moses Dennison
ESErica Ollmann Saphire
Erica Ollmann Saphire
Community of antibodies against COVID-19: The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie et al . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV

19 November 2021 in Science Immunology
Verified
Journal Article
Open access
MPMaya M.L. Poon
Maya M.L. Poon
KRKsenia Rybkina
Ksenia Rybkina
YKYu Kato
Yu Kato
MKMasaru Kubota
Masaru Kubota
RMRei Matsumoto
Rei Matsumoto
DFDonna L. Farber
Donna L. Farber
SARS-CoV-2–specific memory cells persist in multiple sites months after infection, particularly in lungs and associated lymph nodes.

2 June 2017 in Science
Verified
Journal Article
Closed access
PDF file
KHKathryn M. Hastie
Kathryn M. Hastie
MZMichelle A. Zandonatti
Michelle A. Zandonatti
LKLara M. Kleinfelter
Lara M. Kleinfelter
MHMegan L. Heinrich
Megan L. Heinrich
MRMegan M. Rowland
Megan M. Rowland
ESErica Ollmann Saphire
Erica Ollmann Saphire
The crystal structure of an antibody–viral glycoprotein complex illuminates viral entry mechanisms and provides a blueprint for vaccine design.

17 June 2022 in Science Advances
Verified
Journal Article
Open access
HCHeather M. Callaway
Heather M. Callaway
DZDawid S Zyla
Dawid S Zyla
FLFlorence Larrous
Florence Larrous
GMGuilherme Dias de Melo
Guilherme Dias de Melo
KHKathryn M. Hastie
Kathryn M. Hastie
ESErica Ollmann Saphire
Erica Ollmann Saphire
Rabies infection is nearly 100% lethal if untreated and kills more than 50,000 people annually, many of them children. Existing rabies vaccines target the rabies virus glycoprotein (RABV-G) but generate short-lived immune responses, likely because the protein is heterogeneous under physiological conditions. Here, we report the 3.39 Å cryo–electron microscopy structure of trimeric, prefusion RABV-G complexed with RVA122, a potently neutralizing human antibody. RVA122 binds to a quaternary epitope at the top of RABV-G, bridging domains and stabilizing RABV-G protomers in a prefusion state. RABV-G trimerization involves side-to-side interactions between the central α helix and adjacent loops, rather than contacts between central helices, and interactions among the fusion loops at the glycoprotein base. These results provide a basis from which to develop improved rabies vaccines based on RABV-G stabilized in the prefusion conformation.

22 July 2022 in Science Advances
Verified
Journal Article
Open access
MNMichael J Norris
Michael J Norris
MHMonica L. Husby
Monica L. Husby
WKWilliam B. Kiosses
William B. Kiosses
JYJieyun Yin
Jieyun Yin
RSRoopashi Saxena
Roopashi Saxena
ESErica Ollmann Saphire
Erica Ollmann Saphire
Measles virus, Nipah virus, and multiple other paramyxoviruses cause disease outbreaks in humans and animals worldwide. The paramyxovirus matrix (M) protein mediates virion assembly and budding from host cell membranes. M is thus a key target for antivirals, but few high-resolution structures of paramyxovirus M are available, and we lack the clear understanding of how viral M proteins interact with membrane lipids to mediate viral assembly and egress that is needed to guide antiviral design. Here, we reveal that M proteins associate with phosphatidylserine and phosphatidylinositol 4,5-bisphosphate [PI(4,5)P 2 ] at the plasma membrane. Using x-ray crystallography, electron microscopy, and molecular dynamics, we demonstrate that PI(4,5)P 2 binding induces conformational and electrostatic changes in the M protein surface that trigger membrane deformation, matrix layer polymerization, and virion assembly.